For millions of people living with heart failure, the prospect of recovery often feels out of reach. While medical advancements have provided tools to manage symptoms and stabilize patients, the ability to repair the heart muscle itself remains a significant challenge. However, a recent study published in the Journal of the American Heart Association may have identified a critical biological piece of this complex puzzle: a protein that appears to play a central role in how the heart recovers its function.
Researchers have found that a protein known as PERM1 is fully restored in patients whose hearts show meaningful recovery after being supported by mechanical pumps, known as left ventricular assist devices (LVADs). Conversely, this restoration was absent in patients whose heart function did not improve. This discovery offers a new window into the molecular mechanisms that may dictate whether a failing heart can successfully repair itself, potentially paving the way for future therapies that go beyond current management strategies.
Understanding Heart Failure and the Role of LVADs
Heart failure affects more than 6 million adults in the United States, according to the American Heart Association. It is a chronic, progressive condition where the heart is unable to pump blood as effectively as it should. For patients with advanced stages of the disease, clinicians often utilize LVADs—mechanical pumps that support the heart’s left ventricle—to reduce strain and allow the organ to rest. While these devices can be life-saving and provide essential stabilization, only a subset of patients experience significant, lasting recovery of their own heart function.
The reasons behind this disparity have long been a subject of intense investigation. By analyzing heart tissue samples from 19 patients, a research team from Virginia Tech’s Fralin Biomedical Research Institute at VTC and the University of Utah sought to identify the biological signals that distinguish “responders”—those whose hearts recover—from “non-responders.”
The Discovery of PERM1
The study, which combined molecular research with clinical cardiac care, revealed that PERM1 levels were reduced in all patients prior to the implantation of an LVAD. Following the use of the device, however, the researchers observed a distinct difference: in patients whose hearts recovered, PERM1 levels returned to near-normal. In those who did not show functional improvement, the protein levels remained suppressed.
“This is the first muscle-specific molecular signal linked to recovery in human heart failure,” said Junco Warren, a cardiovascular molecular researcher and assistant professor at the Fralin Biomedical Research Institute, who served as a co-corresponding author on the study. “We don’t yet know whether PERM1 drives recovery or reflects it, but it gives us a clear window into the biology of how recovery happens.”
PERM1 is known to regulate how heart cells—or cardiomyocytes—produce and utilize energy. The researchers found that recovery was strongly associated with the normalization of metabolic pathways that manage stress. Because heart failure often involves a cycle where energy loss and reduced contraction reinforce each other, the restoration of PERM1 may be a key factor in breaking this cycle.
Potential for Future Therapies
While the current study provides a significant step forward in understanding the biology of heart recovery, the researchers emphasize that further investigation is required to determine whether PERM1 directly causes the recovery or is simply a marker of it. Stavros Drakos, a professor of cardiology at the University of Utah and co-corresponding author, noted the importance of these findings for future clinical applications. “Identifying the biological signals behind recovery is essential to improving outcomes for patients with advanced heart failure,” Drakos stated.
The implications of this research extend beyond identifying a biomarker. Because current treatments for heart failure generally focus on symptom management rather than muscle repair, the team is looking toward the development of novel therapies. Warren, who is also an assistant professor in Virginia Tech’s College of Agriculture and Life Sciences, noted that the pathway identified directly targets the cardiomyocytes, aiming to restore both contractile function and energy production. To help advance these findings toward patient care, members of the research team have co-founded a company focused on developing PERM1-based gene therapies.
Advancing Cardiac Research
The study received support from several major health and research organizations, including the National Institutes of Health, the American Heart Association, the US Department of Veterans Affairs, and the Nora Eccles Treadwell Foundation. As the scientific community continues to study the role of PERM1, the focus will likely shift toward clinical trials and the potential for translating these molecular findings into actionable treatments for patients.
For those interested in the latest developments in cardiovascular health, the Journal of the American Heart Association provides ongoing updates on peer-reviewed studies regarding heart failure and cardiac recovery. As research progresses, these findings offer a renewed sense of optimism for the millions of individuals facing the challenges of advanced heart disease.
Have you or a loved one been affected by heart failure? We invite you to share your thoughts or questions in the comments section below. Stay tuned to World Today Journal for further updates on this developing medical story.